What is Tarsus Pharmaceuticals, Inc.'s market cap?

Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.6B and trades on NASDAQ.

What is Tarsus Pharmaceuticals, Inc.'s revenue and profitability?

Tarsus Pharmaceuticals, Inc. generated $535.1M in trailing twelve-month revenue with a net loss of $48.3M, representing a net margin of -9.0%. Gross margin stands at 42.7%, with free cash flow of -$104.4M. These figures are based on the Q1 2026 filing.

Who are Tarsus Pharmaceuticals, Inc.'s competitors?

Tarsus Pharmaceuticals, Inc.'s key competitors include Bausch + Lomb, Alcon, AbbVie, and others. These companies compete in similar markets and product categories.

Where is Tarsus Pharmaceuticals, Inc. headquartered?

Tarsus Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 244 people. It has been publicly traded since 2020.

Tarsus Pharmaceuticals, Inc.

TARS

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for high unmet medical needs, with an initial focus on eye care.

Market cap

$2.62B+56.1%

Revenue$535.1M+129%

Net income-$48.3M+54.0%

Free cash flow-$104.4M-2.6%

EPS (diluted)-$1.13+58.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$162.1MBeat by $12.5M EPS-$0.16Beat by $0.24

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$169.1M

EPS estimate-$0.21

Financials

Q1 2026

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation & ratios

Valuation

See full

Market cap$2.62B+56.1%

Enterprise value$2.61B+51.0%

P/S4.9×-1.0×

Profitability

See full

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Segments

By segment

See full

Reportable Segment$162.1M+107%

Competitors

By market cap

AbbVie$453.91B+36.3%

Alcon$32.8B-26.4%

Bausch + Lomb$5.8B+13.7%

Tarsus Pharmaceuticals, Inc.$2.6B+49.5%

Ocular Therapeutix$1.9B-1.7%

HRO

Harrow$1.4B+9.1%

LENZ Therapeutics, Inc.$178.7M-79.8%

Aldeyra Therapeutics$95.6M-70.0%

By revenue growth

Tarsus Pharmaceuticals, Inc.+129%

Ocular Therapeutix-12.8%

By net margin

AbbVie5.79%-1.5pp

Bausch + Lomb-3.21%+2.4pp

Tarsus Pharmaceuticals, Inc.-9.02%+35.9pp

HRO

Harrow-19.75%+1.0pp

Ocular Therapeutix-558.24%-235pp

Profile

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for high unmet medical needs, with an initial focus on eye care. The company's core value proposition centers on its proprietary lotilaner-based platform, which targets and eradicates parasite infestations to treat inflammatory and infectious diseases.

Competitive position

Tarsus holds a first-mover advantage with the only FDA-approved therapeutic for Demodex blepharitis.

GeographiesUnited States

Customer segmentsHealthcare Providers, Patients

Business modelR&D-based drug development, Direct pharmaceutical sales

SuppliersActive pharmaceutical ingredient (API) manufacturers, Contract Research Organizations (CROs), Specialized chemical suppliers

CustomersSpecialty pharmacies, Pharmaceutical wholesalers, Hospitals and clinics

CountryUnited States of America

Listed2020

Employees244.0

CEOBobak R. Azamian

SectorHealthcare

IndustryBiotechnology

Websitetarsusrx.com

FilingsSEC EDGAR

Ask your AI about Tarsus Pharmaceuticals, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s market cap?: Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.6B and trades on NASDAQ.
What is Tarsus Pharmaceuticals, Inc.'s revenue and profitability?: Tarsus Pharmaceuticals, Inc. generated $535.1M in trailing twelve-month revenue with a net loss of $48.3M, representing a net margin of -9.0%. Gross margin stands at 42.7%, with free cash flow of -$104.4M. These figures are based on the Q1 2026 filing.
Who are Tarsus Pharmaceuticals, Inc.'s competitors?: Tarsus Pharmaceuticals, Inc.'s key competitors include Bausch + Lomb, Alcon, AbbVie, and others. These companies compete in similar markets and product categories.
Where is Tarsus Pharmaceuticals, Inc. headquartered?: Tarsus Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 244 people. It has been publicly traded since 2020.